CB Scientific : Entry into Material Definitive Agreement

CB SCIENTIFIC, INC.

Entry into Material Definitive Agreement

CB Scientific, Inc. (CBSC) and Shenzhen Pump Medical Co., Ltd. Announce Cooperative Manufacturing Agreement for Chinese Market

August 23, 2022

(Date of Report)

CB SCIENTIFIC, INC.

(Exact Name of Registrant as Specified in its Charter)

340 State Place, Escondido, CA 92029

(Address of principle executive offices)

888-225-0870

(Registrant's telephone number, including area code)

CB Scientific, Inc. (CBSC)

CB Scientific, Inc. (CBSC) and Shenzhen Pump Medical Co., Ltd. Announce Cooperative Manufacturing Agreement for Chinese Market

CB Scientific. Inc., a designer, manufacturer and distributor of non-invasive ambulatory cardiac monitoring products and services, is pleased to announce that it has entered into a cooperative manufacturing agreement (CMA) with Shenzhen Pump Medical Co., Ltd. (Shenzhen Pump), a privately held, well-established medical device manufacturer, developer and distributor of cardiovascular medical equipment and devices based in Shenzhen, Nanshan, China.

Under the terms of the CMA, Shenzhen Pump will formally be recognized as the qualified manufacturer of record in China for the Company's innovative myCam cardiac event monitor, interactive cloud-based acquisition software, and the associated WeChat smartphone app. As a certified ISO 13485, and Quality Systems Regulations compliant device manufacturer in that country, Shenzhen Pump fulfills the manufacturing regulatory requirements of the National Medical Products Administration (NMPA - formally China's FDA) medical device regulatory approval process for the Company's myCam device in China.

CBSC plans to immediately commence collaboration with Shenzhen Pump to prepare their facility for myCam device manufacturing, deployment of a new Chinese cloud-based software portal for validation, test and support purposes, as well as development of an enhanced WeChat smartphone app to seamlessly function with the newly manufactured devices. Subsequent to a successful NMPA audit confirming that Shenzhen Pump meets requisite manufacturing standards, a limited number of pre-production myCam devices will be placed with existing hospital evaluation locations for final validation performance testing.

This is a very important step in CB Scientific's strategic plans to become a major player in the Asian markets for its non-invasive ambulatory cardiac monitoring products and services, where the populations total over 1.6 billion people in its target markets in China, Malaysia, Thailand, Indonesia, and Singapore.

CB Scientific plans to make further announcements to keep its shareholders, industry participants and the public markets informed through press releases and regulatory filings, on important new developments.

Company Contact Information:

Address:

340 State Place

Escondido, CA 92029

Telephone number: [phone]

Emails:

General inquires:[e-mail]

Investor Inquiries:[e-mail]

Social Media Outlets:

Twitter, Facebook, Instagram, and LinkedIn

This information disclosure may contain forward-looking statements covered within the meaning of the Private Securities Litigation Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions and plans contained in this press release that are not historical fact and involve risks and uncertainties. Our expectations regarding future revenues depend upon our ability to develop and supply products and services that we may not produce today and that meet defined specifications. When used in this press release, the words "plan," "expect," "believe," and similar expressions generally identify forward- looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets. This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.

SIGNATURES

The Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: August 23, 2022

CB SCIENTIFIC, INC.

By: /s/ Charles Martin

Charles Martin,

President